Aurobindo Pharma, Hyderabad-based manufacturer of generic and active pharmaceutical ingredients reported a net profit of Rs 103.2 crore for the quarter ended September 30, 2009, as against a net loss of Rs 38.4 crore during the corresponding period last year. Revenues were up 24.42 per cent to Rs 882.64 crore as compared with Rs 709.4 crore last year.
The company made a forex gain of Rs 3.7 crore during the quarter as against a loss of Rs 85.3 crore last year. Formulations sales increased 39.4 per cent to Rs 445.2 crore during the period as compared with Rs 319.3 crore, managing director K Nithyananda Reddy said in a release.
Aurobindo had three abbreviated new drug applications and 16 dossier filings during the quarter.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app